| چکیده انگلیسی مقاله |
Background: Primary immunodeficiency diseases (PID) are heterogeneous group of inherited disorders mainly characterized by recurrent infections leading to several times hospital admissions. The economic impact of PID is a challenging issue; therefore, this study was designed to determine the medical costs of hospitalizations in this group of patients as an indicator of the direct cost of these diseases. Methods: One hundred and ten children with PID hospitalized in the Children’s Medical Center Hospital, Tehran, Iran were included in this study during Jan 2011 and Jan 2012. All direct costs during the admission period were calculated, using the hospital information system. Results: Medical cost was 7.090$ per patient per admission. Among them, about 1.580$ belong to drug consuming during hospitalization. Anti-infective drugs for systemic use were the most cost-consuming group of drugs, followed by alimentary tract and metabolism and blood and blood forming organs agents. Investigation of anti-infective group internally showed that immune sera and immunoglobulin and antiviral agents for systemic use consisting the most important medication for PID patients during hospital admission. Conclusion: Although the results of economic evaluations in a region cannot necessarily be applied to other regions, having an overall estimation of hospital admission costs and types of drugs used during admission could be helpful in health policy system. |
| نویسندگان مقاله |
| Kheirollah GHOLAMI
Dept. of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran
| Elaheh LAALI
Dept. of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| Hassan ABOLHASSANI
Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran Primary Immunodeficiency Diseases Network (PIDNet), Universal Scientific Education and Research Network (USERN), Stock-holm, Sweden
| Alireza AHMADVAND
School of Clinical Sciences, Queensland University of Technology, Brisbane, Australia
| Niayesh MOHEBBI
Dept. of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| Mohammad Reza JAVADI
Dept. of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran
| Asghar AGHAMOHAMMADI
Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran Primary Immunodeficiency Diseases Network (PIDNet), Universal Scientific Education and Research Network (USERN), Tehran, Iran
| Nima REZAEI
Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran Dept. of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran
|